Archive

« Older Entries

Henri Termeer joins Prosensa as Strategic Advisor Thursday, December 13th, 2012
Leiden, The Netherlands – 13 December 2012 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has appointed industry leader and former Genz [...]
Celladon Corporation Announces First European Patient Dosed in CUPID Phase 2b Trial of MYDICAR® for Advanced Heart Failure Tuesday, December 11th, 2012
SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed [...]
Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance Thursday, December 6th, 2012
Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples Holzgerlingen, Germany, December 6, 2012 -- Curetis AG today announced the start of a clinical trial of its Unyvero™ System and the corresponding [...]
arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform Thursday, December 6th, 2012
Breda, the Netherlands, and Ghent, Belgium, December 6, 2012 – arGEN-X, a biopharmaceutical company focused on the discovery and development of highly differentiated human monoclonal antibody therapeutics has received [...]
Okairos named as one of Windhover’s Top Projects to Watch in infectious diseases Wednesday, November 28th, 2012
Basel, Switzerland – 28 November 2012 – Windhover Information has named Okairos as one of its Top Projects to Watch at the 4th Annual Therapeutic Area Partnerships, one of the biopharmaceutical industry’s premier p [...]
SAVE THE DATE: Biotech Update 2013 Tuesday, November 20th, 2012
Biotech Update 2013 Friday 28th June 2013 Kasteel De Wittenburg in Wassenaar, The Netherlands [...]
BioCapitalEurope 2013 Tuesday, November 20th, 2012
BioCapitalEurope Wednesday 17th April 2013 BioCapital Europe 2013, organised by LSP (Life Sciences Partners) and ABN AMRO, is delighted to announce its 11th consecutive event, taking place on Wednesday 17th April 2 [...]
Kiadis Pharma Raises EUR 10 Million in Financing Round Tuesday, November 20th, 2012
Amsterdam, The Netherlands, November 20, 2012 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it has raised EUR 10 million in an equity fin [...]
International Consortium Awarded €6M to Validate Pre-Eclampsia Early Detection Tests Monday, November 5th, 2012
Cork, Ireland and Ghent, Belgium – 5 November 2012 – The European Union has awarded 6 million euro of research funding under the FP7-health framework to a consortium which is working to bring a predictive test for pr [...]
arGEN-X appoints Dr. David L. Lacey to its Supervisory Board Thursday, October 25th, 2012
Breda, the Netherlands and Ghent, Belgium October; 25 October 2012 – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ [...]

« Older Entries

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

Archive

« Older Entries

Henri Termeer joins Prosensa as Strategic Advisor Thursday, December 13th, 2012
Leiden, The Netherlands – 13 December 2012 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has appointed industry leader and former Genz [...]
Celladon Corporation Announces First European Patient Dosed in CUPID Phase 2b Trial of MYDICAR® for Advanced Heart Failure Tuesday, December 11th, 2012
SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed [...]
Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance Thursday, December 6th, 2012
Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples Holzgerlingen, Germany, December 6, 2012 -- Curetis AG today announced the start of a clinical trial of its Unyvero™ System and the corresponding [...]
arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform Thursday, December 6th, 2012
Breda, the Netherlands, and Ghent, Belgium, December 6, 2012 – arGEN-X, a biopharmaceutical company focused on the discovery and development of highly differentiated human monoclonal antibody therapeutics has received [...]
Okairos named as one of Windhover’s Top Projects to Watch in infectious diseases Wednesday, November 28th, 2012
Basel, Switzerland – 28 November 2012 – Windhover Information has named Okairos as one of its Top Projects to Watch at the 4th Annual Therapeutic Area Partnerships, one of the biopharmaceutical industry’s premier p [...]
SAVE THE DATE: Biotech Update 2013 Tuesday, November 20th, 2012
Biotech Update 2013 Friday 28th June 2013 Kasteel De Wittenburg in Wassenaar, The Netherlands [...]
BioCapitalEurope 2013 Tuesday, November 20th, 2012
BioCapitalEurope Wednesday 17th April 2013 BioCapital Europe 2013, organised by LSP (Life Sciences Partners) and ABN AMRO, is delighted to announce its 11th consecutive event, taking place on Wednesday 17th April 2 [...]
Kiadis Pharma Raises EUR 10 Million in Financing Round Tuesday, November 20th, 2012
Amsterdam, The Netherlands, November 20, 2012 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it has raised EUR 10 million in an equity fin [...]
International Consortium Awarded €6M to Validate Pre-Eclampsia Early Detection Tests Monday, November 5th, 2012
Cork, Ireland and Ghent, Belgium – 5 November 2012 – The European Union has awarded 6 million euro of research funding under the FP7-health framework to a consortium which is working to bring a predictive test for pr [...]
arGEN-X appoints Dr. David L. Lacey to its Supervisory Board Thursday, October 25th, 2012
Breda, the Netherlands and Ghent, Belgium October; 25 October 2012 – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ [...]

« Older Entries

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview